|Title:||Use of inhibitors of Bruton's tyrosine kinase (Btk)|
|Abstract:|| Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.|
|Inventor(s):|| Buggy; Joseph J. (Mountain View, CA), Elias; Laurence (Berkeley, CA), Fyfe; Gwen (San Francisco, CA), Hedrick; Eric (Summit, NJ), Loury; David J. (Incline Village, NV), Mody; Tarak D. (Sunnyvale, CA) |
|Assignee:|| Pharmacyclics, Inc. (Sunnyvale, CA) |
1. A method for treating Waldenstrom's macroglobulinemia in an individual who has already received at least one prior therapy for Waldenstrom's macroglobulinemia comprising
administering to the individual once per day between about 420 mg to about 840 mg of an oral dose of an inhibitor of Bruton's tyrosine kinase (Btk) having the structure: ##STR00047##
2. The method of claim 1, wherein the once per day oral dose is about 420 mg.